388870 — Pharos IBio Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for Pharos IBio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	57	300	0	0	0
Cost of Revenue
Gross Profit	30.3	130	0	0	0
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	8,463	10,919	10,117	12,601	11,507
Operating Profit	-8,406	-10,619	-10,117	-12,601	-11,507
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-31,471	-17,062	-8,858	-10,560	-10,757
Provision for Income Taxes
Net Income After Taxes	-31,471	-17,062	-8,858	-10,560	-10,757
Net Income Before Extraordinary Items
Net Income	-31,471	-17,062	-8,858	-10,560	-10,757
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-31,471	-17,062	-8,858	-10,560	-10,757
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-2,436	-1,323	-729	-814	-831
Dividends per Share